Mingchen Health (002919) Fundamentals 2026 — P/E 191.3x, Revenue Analysis | SniperIQ
Mingchen Health (002919) is a CN-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ¥4.4B, trading at ¥16.57 on the SHZ. This SniperIQ fundamentals page covers Mingchen Health's valuation (P/E 191.3x, P/B 5.4x), profitability (net margin 1.6%), revenue (¥1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mingchen Health's market cap?
Mingchen Health (002919) has a market capitalization of approximately ¥4.4B, trading at ¥16.57 on the SHZ. Market cap moves with the live share price.
What is Mingchen Health's P/E ratio?
Mingchen Health's trailing twelve-month P/E ratio is 191.3x, with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Mingchen Health?
Mingchen Health runs a net profit margin of 1.6%, a gross margin of 55.0%, and an operating margin of 0.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mingchen Health generate?
Mingchen Health reported revenue of ¥1.5B for fiscal year 2025, with net income of ¥28M and earnings per share (EPS) of 0.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mingchen Health pay a dividend?
Mingchen Health offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Mingchen Health financially healthy?
Mingchen Health carries a debt-to-equity ratio of 0.12x and a current ratio of 1.73x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mingchen Health a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mingchen Health (002919) the key facts are: market cap ¥4.4B, P/E 191.3x, revenue ¥1.5B, 52-week range 14.29-27.9. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Mingchen Health's full fundamentals live
Get Mingchen Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.